Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 10, 2007

Transgenomic Inks Analysis Agreement with OSI

  • Transgenomic signed a contract with OSI Pharmaceuticals to complete an analysis of specific cancer pathway genes. According to the company, it has developed a high-throughput, high-sensitivity methodology for characterizing genetic variants implicated in malignant neoplasia. Transgenomic can detect pathogenic genetic mutations through use of high-throughput genome scanning with endonucleases, forward and reverse Sanger sequencing, and variant annotation.

    "The contract with OSI Pharmaceuticals enables Transgenomic to utilize its expertise in genetic variant detection to assist OSI Pharmaceuticals in its development efforts. This contract follows genetic analysis work done with other pharmaceutical companies. It is one of the ways Transgenomic can contribute to the development of therapeutics that benefits patients," states Transgenomic's president and CEO, Craig Tuttle. 



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »